Stryker Corporation (SYK), a medical technology company, is widely covered by Wall Street, and the $360 central target reflects a genuine arithmetic mean rather than a single firm's view. The targets reviewed range from about $298 to $420, with a median near $360, producing a mean of roughly $360.60 that rounds to $360. That figure is consistent with independent aggregator averages of approximately $357 to $367, though the highest figures in some datasets reach about $465.
The spread between the low and high targets is unusually wide, underscoring genuine disagreement. Bulls such as Needham ($418) and RBC Capital ($420) emphasize Mako robotic-assisted surgery growth and a strong equipment backlog. More cautious firms sit much lower: TD Cowen cut its target to $298, and Truist Securities to $310, both citing softer revenue and earnings commentary from September investor conferences. Several firms trimmed targets in early October — including BMO Capital ($369 to $317), BTIG ($358 to $316), and Leerink Partners ($403 to $353) — reflecting unresolved manufacturing disruptions rather than a loss of long-term conviction.
Shares of Stryker recently traded around $307, near the midpoint of a 52-week range spanning roughly $267 to $392. Reaching $360 would require an advance of about 17%, a substantial move by any standard but not an extraordinary one for a large-cap name that has routinely traded above that level in the past year.
The path is complicated by recent volatility. In early September 2026 the stock fell about 9% in a single session after management disclosed that a manufacturing issue previously thought resolved was still affecting operations. Separately, the company has announced that President and COO Spencer Stiles will succeed long-time CEO Kevin Lobo in January 2027, a transition analysts generally view as low-risk but which adds near-term uncertainty. Valuation is another consideration: the stock trades at a forward P/E (price-to-earnings ratio) in the mid-teens on forward estimates, below the elevated multiples medtech names carried earlier in the cycle.
Stryker's core fundamentals remain intact. The company reported second-quarter 2026 revenue of about $6.59 billion and net income of roughly $1.28 billion, with EPS (earnings per share) beating consensus. Demand for elective procedures, orthopedic implants, and capital equipment has stayed resilient, and the Mako robotic platform continues to support joint-replacement sales. Analysts also point to a substantial backlog of unfilled equipment orders, growth in ambulatory surgery centers, and innovation such as a newly FDA-cleared Apple Vision Pro surgical application. A resolution of the manufacturing issue would remove the single largest near-term overhang and could prompt target revisions higher.
The manufacturing disruption affecting the Peripheral Vascular and Joint Replacement businesses is the clearest obstacle, and roughly 14 analysts have trimmed next-period earnings estimates. A CEO transition, insider selling by a long-time director, and investigations opened by plaintiffs' law firms add headline risk, even though such inquiries establish no wrongdoing. Broader medtech valuation compression and softer hospital capital spending could also cap multiple expansion. Should the manufacturing issue persist into 2027 or guidance disappoint, the $298 low-end targets could prove more relevant than the $360 mean.
Stryker has been rebuilding from its 52-week low near $267, recovering toward the $307 area while remaining below its 200-day moving average near $325. That $325–$330 zone represents a meaningful resistance level, and a sustained move above it would be an important structural signal. On the downside, the $275–$280 region marks recent support, with the $267 low as a more durable floor. The $360 target itself sits in a relatively open technical gap between the 200-day average and the prior 52-week high near $392, meaning there is no dense resistance cluster immediately between the current price and the target.
Most analyst price targets reflect a roughly 12-month research horizon, though individual firms apply different assumptions. The next key checkpoint is the company's quarterly earnings report, scheduled around late October 2026, where investors will watch third-quarter results, margin commentary, and any update on the manufacturing disruption. Beyond that, the January 2027 CEO transition, any further analyst estimate revisions, and the pace of Mako robotics adoption are the most important variables to track. Macroeconomic factors such as hospital capital budgets and interest rates also influence the medtech sector broadly.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors following Stryker's price action and broader market structure, these signals can serve as a supplemental, data-driven lens rather than a replacement for fundamental research.
The $360 central target is a calculated mean of individual analyst price targets, not a published official consensus or a guarantee, and it implies a substantial gain of roughly 17% from recent levels. The case for reaching it rests on resilient procedure volumes, Mako robotics momentum, a large equipment backlog, and a potential resolution of the manufacturing disruption. The case against rests on that same manufacturing issue, a leadership transition, estimate cuts, and sector-wide valuation pressure. With targets spanning from $298 to $420 — and some datasets higher — the wide dispersion is itself a signal that investors should weigh the range, not any single number. The upcoming earnings report and management's guidance will be the clearest near-term tests of which end of that range is more likely to prevail.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To SYK | 1D Price Change % |
|---|---|---|
| SYK | 100% | -6.38% |
| Health Services category (239 stocks) | 3% Poorly correlated | -1.35% |
| Medical/Nursing Services category (138 stocks) | 1% Poorly correlated | -1.17% |